Literature DB >> 10493309

The usefulness of in vivo gene expression investigations from peripheral white blood cells: a preliminary study.

I Ember1, I Kiss, T Raposa.   

Abstract

Alterations of onco/tumour suppressor genes are involved in the formation of human hematological malignancies. Previously, in animal models, we demonstrated the applicability of in vivo gene expression investigations to monitor the effects of certain carcinogenic chemicals. In our present study we determined the expression of onco/suppressor genes from isolated peripheral white blood cells of patients with chronic myeloid leukaemia (CLL) and non-Hodgkin lymphoma (NHL). Gene expressions were determined by isolation of total RNA and slot blot hybridization with chemiluminescently labeled gene probes (Ha-ras, c-myc and p53) Expression levels were compared before and after treatment with a combined cytostatic protocol, containing cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). Both the CLL and NHL group of patients exhibited significantly higher expression of the investigated genes than healthy controls. One month after the cytostatic treatment, we found considerably fewer individuals with overexpressed oncogenes than before the treatment. Our study proved that onco/tumour suppressor gene expressions could be used as biomarkers of certain hematological malignancies, and to monitor the therapeutical effect of cytostatic drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493309     DOI: 10.1097/00008469-199908000-00010

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  1 in total

1.  Changes in expression of oncogenes and TP53 tumour suppressor gene as biomarkers in head and neck cancers.

Authors:  István Szanyi; Miklós Bauer; Imre Gerlinger; Tamás Járai; Gyula Gobel; László Lujber; Eva Szabadi; Katalin Fehér; Agoston Émber; István Ember; István Kiss
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-12-01       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.